The Biological Intelligence Era

The consequences are no longer defensible

Women have spent decades navigating a healthcare system that records symptoms, biomarkers and life events as separate encounters, then struggles to explain what those signals mean together.

Hormonal changes are routinely assessed through isolated measurements. Symptoms are divided among specialties. Consumer devices generate expanding volumes of physiological data without connecting them to clinical history, reproductive stage or individual baseline. Women are left to assemble the fragments and explain, repeatedly, what has been changing in their own bodies.

This is not a failure of women’s biology. It is a failure of the model used to understand it.

Women’s health has too often been described as unusually complex when the deeper problem is that healthcare continues to rely on episodic testing for biology that is dynamic, interconnected and profoundly influenced by time. A result can be analytically accurate while remaining clinically or personally incomplete. Without cycle context, reproductive stage, symptoms, medication, stress, sleep and longitudinal history, a number may tell us what was measurable at one moment while revealing very little about the pattern taking shape.

The market’s response has been to create more tests, more applications, more wearables and more dashboards. Measurement has expanded. Understanding has not kept pace.

That distinction now defines one of the most important opportunities in healthcare. The next generation of women’s-health testing must move beyond isolated detection. It must establish continuity across biomarkers, symptoms, physiological signals and life stages. It must distinguish individual baseline from population range, fluctuation from sustained change and pattern recognition from diagnosis.

Biology is longitudinal

Human biology does not move in clean, independent lines. Hormones interact with sleep, metabolism, stress, inflammation, medication, activity, injury, nutrition and age. The meaning of one signal may depend on its relationship to several others, as well as on the individual’s own baseline and trajectory.

This is why longitudinal information matters. Repeated observation can reveal direction, variability, recurrence and response. It can help distinguish a one-time deviation from a persistent change and can make visible relationships that isolated measurements are not designed to show.

Recent research is beginning to demonstrate what becomes possible when physiological signals, hormone measurements, metabolic data and reported symptoms are studied together over time. A newly published multimodal menstrual-health dataset, for example, combines wearable signals, continuous glucose data, at-home hormone testing and daily symptom and lifestyle reporting. Its importance is not that it settles clinical questions. It is that it provides the kind of connected, longitudinal foundation from which better questions and predictive methods can emerge.¹

Women reveal the system’s blind spot

The limitations of snapshot-based healthcare are especially visible in women’s health. A biological reading cannot always be interpreted well without knowing where a woman is in her menstrual cycle, whether she uses hormonal contraception, whether she is postpartum, or whether she is moving through perimenopause or menopause.

Emerging evidence continues to show that physiological and biomarker patterns can vary across cycle phases, contraceptive use and reproductive life stages. A 2026 study reported cycle- and contraception-related differences in several cardiovascular biomarkers. A recent living systematic review found that wearable-derived heart-rate variability is associated with menstrual-cycle phase, hormonal contraceptive use and reproductive life stage, while also warning that inconsistent phase classification and limited hormone confirmation weaken interpretation across studies.^2,3

That is not an argument that every fluctuation is clinically meaningful or that consumer data should be treated as diagnosis. It is the opposite. It is an argument for greater interpretive discipline. Context must constrain the conclusion.

The broader institutional gap is well documented. The National Academies concluded that insufficient research into the biological and social factors affecting chronic conditions in women continues to hinder diagnosis, treatment and prevention. NIH’s current women’s-health strategy likewise calls for research across the life course, improved data science and management, innovative measurement and a better understanding of how biological, behavioural, social and environmental factors intersect.^4,5

Women have been expected to navigate what they were never taught

Women are expected to manage decades of endocrine change with remarkably little structured information about how their own hormonal life cycle works. Hormones are discussed most often in relation to menstruation, contraception, fertility or menopause, as though these were isolated subjects rather than connected stages of reproductive life.

Basic cycle literacy is still not treated as health infrastructure. Many women are never given a practical framework for understanding the follicular, ovulatory and luteal phases; how patterns can differ among individuals and across time; or how stress, sleep, illness, medication, pregnancy, postpartum recovery, hormonal contraception, nutrition and aging may alter symptoms, timing or the interpretation of a result.

Perimenopause makes the cost of that information gap especially clear. It is often treated as a brief prelude to menopause rather than a multi-year transition with early and late stages, changing cycle patterns and hormone levels that may fluctuate unpredictably. Menopause itself is identified retrospectively after 12 consecutive months without menstruation. By then, a woman may already have spent years experiencing changes in sleep, temperature regulation, mood, cognition, bleeding, sexual health, urinary function or metabolism without a coherent explanation connecting them.^8,9

This is not a knowledge failure on the part of women. It is a failure to deliver accessible, longitudinal health information before women are forced to search for answers in the middle of a transition. A testing model designed for women must therefore do more than return a number. It must help place that number within cycle phase, reproductive stage, personal baseline and the other conditions capable of shaping its meaning.

More data is not the same as greater understanding

The consumer-health market has responded to unmet need with a flood of devices and applications. The result is access to more signals, but those signals often remain divided among different products, accounts, formats and commercial interests.

A wearable may identify a change in sleep or heart-rate variability. An at-home test may produce a biomarker result. A symptom tracker may capture fatigue, pain or mood. A clinical record may contain medication, diagnosis and laboratory history. Each source sees part of the person. Few are designed to understand the relationship among them.

This creates a new kind of fragmentation. The old system scattered information among providers and institutions. The emerging system can scatter it across consumer devices and digital platforms as well. Collection without continuity can generate more dashboards while leaving the underlying question unanswered: what has been changing, and what deserves attention?

From health data to biological intelligence

Biological intelligence is the responsible conversion of multiple biological and experiential signals into contextual understanding over time. It is not a single test, a static score or an automated diagnosis. It is a layer of interpretation.

That layer requires several capabilities working together: repeatable measurement; time and life-stage context; the ability to connect different data types; individualized baselines; transparent analytical methods; and clear boundaries around what a system can and cannot conclude.

The distinction matters commercially as much as scientifically. Measurement is increasingly abundant. Interpretation that is trusted, portable and useful remains scarce. The most valuable health platforms may therefore be those that can connect fragmented signals without stripping the individual of agency or forcing every insight into a diagnostic claim.

AI changes the opportunity and the obligation

Artificial intelligence can help identify relationships across time, data types and large populations that would be difficult to recognize manually. It may support image analysis, pattern detection, personalization and more efficient clinical or regulatory work. But applying AI to health information raises the standard of responsibility rather than lowering it.

FDA’s current direction for AI-enabled medical devices emphasizes the total product lifecycle, including design, testing, documentation, transparency, bias, performance monitoring and changes after deployment. International principles endorsed by FDA, Health Canada and the United Kingdom’s regulator similarly place transparency and human understanding at the centre of responsible machine-learning-enabled medical devices.^6,7

In practical terms, an intelligent health platform must know the difference between identifying a pattern, offering contextual information and making a clinical determination. It must be able to communicate uncertainty. It must be tested on populations representative of its intended use. It must protect consent and authorized use as data moves across systems. And it must be monitored as medical practice, populations and data inputs change.

The technology is powerful. The competitive advantage will come from pairing that power with scientific restraint, governed data and trust.

The market is moving from measurement to meaning

Women’s health does not require another generation of products that measure isolated signals and return the burden of interpretation to the user.

It requires testing designed for change over time. It requires systems capable of connecting biomarkers with symptoms, life stage and individual history. It requires artificial intelligence governed by scientific restraint, transparent boundaries and the individual’s authority over her data.

Fluid Medical is building toward that future through ORIA. ORIA begins with women because the failure of episodic, fragmented healthcare is especially visible in women’s lives. Its purpose is not to convert every biological variation into a diagnosis. Its purpose is to create continuity where the system currently sees fragments and to help transform measurement into meaningful, responsible intelligence.

The market has already produced more data. The next task is to understand it. That is the biological intelligence era, and women’s health should lead it.

For media, research and strategic partnership inquiries, contact Fluid Medical.